Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma

Marianna Vitiello, Monica Evangelista, Nicole Di Lascio, Claudia Kusmic, Annamaria Massa, Francesca Orso, Samanta Sarti, Andrea Marranci, Katarzyna Rodzik, Lorenzo Germelli, Dinesh Chandra, Alessandra Salvetti, Angela Pucci, Daniela Taverna, Francesco Faita, Claudia Gravekamp, Laura Poliseno

Research output: Contribution to journalArticle

Abstract

Attenuated Listeria monocytogenes (Lmat-LLO) represents a valuable anticancer vaccine and drug delivery platform. Here we show that in vitro Lmat-LLO causes ROS production and, in turn, apoptotic killing of a wide variety of melanoma cells, irrespectively of their stage, mutational status, sensitivity to BRAF inhibitors or degree of stemness. We also show that, when administered in the therapeutic setting to Braf/Pten genetically engineered mice, Lmat-LLO causes a strong decrease in the size and volume of primary melanoma tumors, as well as a reduction of the metastatic burden. At the molecular level, we confirm that the anti-melanoma activity exerted in vivo by Lmat-LLO depends also on its ability to potentiate the immune response of the organism against the infected tumor. Our data pave the way to the preclinical testing of listeria-based immunotherapeutic strategies against metastatic melanoma, using a genetically engineered mouse rather than xenograft models.

Original languageEnglish (US)
JournalOncogene
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Listeria monocytogenes
Melanoma
Listeria
Heterografts
Neoplasms
Vaccines
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Vitiello, M., Evangelista, M., Di Lascio, N., Kusmic, C., Massa, A., Orso, F., ... Poliseno, L. (Accepted/In press). Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma. Oncogene. https://doi.org/10.1038/s41388-019-0681-1

Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma. / Vitiello, Marianna; Evangelista, Monica; Di Lascio, Nicole; Kusmic, Claudia; Massa, Annamaria; Orso, Francesca; Sarti, Samanta; Marranci, Andrea; Rodzik, Katarzyna; Germelli, Lorenzo; Chandra, Dinesh; Salvetti, Alessandra; Pucci, Angela; Taverna, Daniela; Faita, Francesco; Gravekamp, Claudia; Poliseno, Laura.

In: Oncogene, 01.01.2019.

Research output: Contribution to journalArticle

Vitiello, M, Evangelista, M, Di Lascio, N, Kusmic, C, Massa, A, Orso, F, Sarti, S, Marranci, A, Rodzik, K, Germelli, L, Chandra, D, Salvetti, A, Pucci, A, Taverna, D, Faita, F, Gravekamp, C & Poliseno, L 2019, 'Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma' Oncogene. https://doi.org/10.1038/s41388-019-0681-1
Vitiello, Marianna ; Evangelista, Monica ; Di Lascio, Nicole ; Kusmic, Claudia ; Massa, Annamaria ; Orso, Francesca ; Sarti, Samanta ; Marranci, Andrea ; Rodzik, Katarzyna ; Germelli, Lorenzo ; Chandra, Dinesh ; Salvetti, Alessandra ; Pucci, Angela ; Taverna, Daniela ; Faita, Francesco ; Gravekamp, Claudia ; Poliseno, Laura. / Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma. In: Oncogene. 2019.
@article{a65fffae3d1d4ac19140d2e00f5f85e0,
title = "Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma",
abstract = "Attenuated Listeria monocytogenes (Lmat-LLO) represents a valuable anticancer vaccine and drug delivery platform. Here we show that in vitro Lmat-LLO causes ROS production and, in turn, apoptotic killing of a wide variety of melanoma cells, irrespectively of their stage, mutational status, sensitivity to BRAF inhibitors or degree of stemness. We also show that, when administered in the therapeutic setting to Braf/Pten genetically engineered mice, Lmat-LLO causes a strong decrease in the size and volume of primary melanoma tumors, as well as a reduction of the metastatic burden. At the molecular level, we confirm that the anti-melanoma activity exerted in vivo by Lmat-LLO depends also on its ability to potentiate the immune response of the organism against the infected tumor. Our data pave the way to the preclinical testing of listeria-based immunotherapeutic strategies against metastatic melanoma, using a genetically engineered mouse rather than xenograft models.",
author = "Marianna Vitiello and Monica Evangelista and {Di Lascio}, Nicole and Claudia Kusmic and Annamaria Massa and Francesca Orso and Samanta Sarti and Andrea Marranci and Katarzyna Rodzik and Lorenzo Germelli and Dinesh Chandra and Alessandra Salvetti and Angela Pucci and Daniela Taverna and Francesco Faita and Claudia Gravekamp and Laura Poliseno",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41388-019-0681-1",
language = "English (US)",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma

AU - Vitiello, Marianna

AU - Evangelista, Monica

AU - Di Lascio, Nicole

AU - Kusmic, Claudia

AU - Massa, Annamaria

AU - Orso, Francesca

AU - Sarti, Samanta

AU - Marranci, Andrea

AU - Rodzik, Katarzyna

AU - Germelli, Lorenzo

AU - Chandra, Dinesh

AU - Salvetti, Alessandra

AU - Pucci, Angela

AU - Taverna, Daniela

AU - Faita, Francesco

AU - Gravekamp, Claudia

AU - Poliseno, Laura

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Attenuated Listeria monocytogenes (Lmat-LLO) represents a valuable anticancer vaccine and drug delivery platform. Here we show that in vitro Lmat-LLO causes ROS production and, in turn, apoptotic killing of a wide variety of melanoma cells, irrespectively of their stage, mutational status, sensitivity to BRAF inhibitors or degree of stemness. We also show that, when administered in the therapeutic setting to Braf/Pten genetically engineered mice, Lmat-LLO causes a strong decrease in the size and volume of primary melanoma tumors, as well as a reduction of the metastatic burden. At the molecular level, we confirm that the anti-melanoma activity exerted in vivo by Lmat-LLO depends also on its ability to potentiate the immune response of the organism against the infected tumor. Our data pave the way to the preclinical testing of listeria-based immunotherapeutic strategies against metastatic melanoma, using a genetically engineered mouse rather than xenograft models.

AB - Attenuated Listeria monocytogenes (Lmat-LLO) represents a valuable anticancer vaccine and drug delivery platform. Here we show that in vitro Lmat-LLO causes ROS production and, in turn, apoptotic killing of a wide variety of melanoma cells, irrespectively of their stage, mutational status, sensitivity to BRAF inhibitors or degree of stemness. We also show that, when administered in the therapeutic setting to Braf/Pten genetically engineered mice, Lmat-LLO causes a strong decrease in the size and volume of primary melanoma tumors, as well as a reduction of the metastatic burden. At the molecular level, we confirm that the anti-melanoma activity exerted in vivo by Lmat-LLO depends also on its ability to potentiate the immune response of the organism against the infected tumor. Our data pave the way to the preclinical testing of listeria-based immunotherapeutic strategies against metastatic melanoma, using a genetically engineered mouse rather than xenograft models.

UR - http://www.scopus.com/inward/record.url?scp=85060330571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060330571&partnerID=8YFLogxK

U2 - 10.1038/s41388-019-0681-1

DO - 10.1038/s41388-019-0681-1

M3 - Article

JO - Oncogene

T2 - Oncogene

JF - Oncogene

SN - 0950-9232

ER -